MS4A1 and B-cell chronic lymphocytic leukemia: We recommend that CLL patients with TP53 disruption, including sub-clonal disease, and UM IGHV should not be treated with CIT and those with NOTCH1 mutation should not be treated with anti-CD20 targeted therapy, particularly as part of a CIT regimen.